Martyrs & Models: Early Returns from the AMNOG Era
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
During the past few months, IQWiG has made several decisions public for recently reviewed drugs. For the first time, a body of evidence exists which can shed some light upon how restrictive and how timely access will be under the new AMNOG legislation regime in Germany. Some brands have been particularly fortunate, however these positive outcomes have more to do with compliance with G-BA’s requests than it has to do with whether the product is actually providing clinical benefit or not. To better understand how the future access environment in Germany will take shape, each of the brands reviewed to date has been assessed for key learnings as brand managers plan for the new Germany. A full assessment against the outcomes in England, Scotland, and France also reveals how demanding the G-BA and IQWiG are shaping up to be.
By Cyrus Chowdhury, Practice Leader, Global Market Access, Insight Strategy Advisors.
Have Your Say
Rate this feature and give us your feedback in the comments section below